Abby Hardy, Author at BioTuesdays

Developments

Immunic completes enrollment for Phase 2 MS trial

Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). IMU-838 is a selective immune modulator that blocks the enzyme...

October 11, 2019

Developments

Frequency Therapeutics gets FDA fast track designation for FX-322; begins Phase 2a study dosing

In addition to receiving FDA fast track designation for FX-322, Frequency Therapeutics (NASDAQ:FREQ) initiated dosing in a Phase 2a clinical study of the drug candidate for the treatment of sensorineural hearing loss...

October 11, 2019

Developments

BrainStorm completes enrollment of Phase 3 ALS trial

BrainStorm Cell Therapeutics (NASDAQ:BCLI) completed enrollment of its 200-patient Phase 3 trial evaluating NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). The NurOwn process involves isolating...

October 11, 2019

Developments

Geron doses first patient in Phase 3 myelodysplastic syndrome trial

Geron (NASDAQ:GERN) dosed the first patient in its Phase 3 clinical trial evaluating imetelstat, a telomerase inhibitor, in lower risk myelodysplastic syndromes (MDSs). MDSs occur when bone marrow cells do not mature...

October 11, 2019

Developments

Mereo navicixizumab gets FDA fast track designation for ovarian cancer

Mereo BioPharma’s (NASDAQ:MREO) navicixizumab received FDA fast track designation for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior...

October 8, 2019

Executive Moves

Zosano Pharma names Steven Lo as CEO

Steven Lo Zosano Pharma (NASDAQ:ZSAN) has appointed Steven Lo as president, CEO and a director, effective Oct. 21. Mr. Lo is departing from his role as CCO at Puma Biotechnology (NASDAQ:PUMA), effective Oct. 18, where...

October 8, 2019

Developments

AVROBIO doses first patient in Phase 1/2 gene therapy trial for cystinosis

AVROBIO (NASDAQ:AVRO) dosed the first patient in its Phase 1/2 clinical trial of AVR-RD-04 gene therapy for the treatment of cystinosis. Caused by a mutation in the cystinosin gene, cystinosis is a lysosomal storage...

October 8, 2019

Developments

FDA approves Pfenex osteoporosis drug

The FDA approved Pfenex’s (NASDAQ:PFNX) PF708 for the treatment of osteoporosis in patients at high risk of fracture. “The FDA’s approval of PF708 marks a major milestone in Pfenex’s history as our first approved...

October 8, 2019

Developments

Ritter Pharma engages AGP to explore strategic alternatives

Ritter Pharmaceuticals (NASDAQ:RTTR) has engaged Alliance Global Partners as a financial advisor to help the company evaluate strategic alternatives. The company is considering a variety of options, including an...

October 7, 2019

Executive Moves

Canaccord names veteran biotech analyst, Edward Nash, as managing director, equity research

Canaccord Genuity appointed Edward Nash as its New York office’s managing director, equity research. Mr. Nash completes Canaccord Genuity’s team of five senior biotechnology analysts and will focus on companies...

October 7, 2019

Author - Abby Hardy

Immunic completes enrollment for Phase 2 MS trial

Frequency Therapeutics gets FDA fast track designation for FX-322; begins Phase 2a study dosing

BrainStorm completes enrollment of Phase 3 ALS trial

Geron doses first patient in Phase 3 myelodysplastic syndrome trial

Mereo navicixizumab gets FDA fast track designation for ovarian cancer

Zosano Pharma names Steven Lo as CEO

AVROBIO doses first patient in Phase 1/2 gene therapy trial for cystinosis

FDA approves Pfenex osteoporosis drug

Ritter Pharma engages AGP to explore strategic alternatives

Canaccord names veteran biotech analyst, Edward Nash, as managing director, equity research

Subscribe